Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2b, Open-label, Multicenter, Randomized Parallel-Group, Two-Stage, Study of an Immunotherapeutic Treatment DPX-Survivac and Pembrolizumab, With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (VITALIZE)

NCT04920617 is registered in ClinicalTrials.gov with ImmunoVaccine Technologies, Inc. (IMV Inc.) as lead sponsor.

NCT NCT04920617
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04920617 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2b, Open-label, Multicenter, Randomized Parallel-Group, Two-Stage, Study of an Immunotherapeutic Treatment DPX-Survivac and Pembrolizumab, With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (VITALIZE)
Lead sponsor
ImmunoVaccine Technologies, Inc. (IMV Inc.)
Phase
Phase 2
Overall status
Recruiting
Start date
June 18, 2021
Completion date
April 30, 2025
Enrollment
102 (estimated)
Sites
50

Conditions

As the registry lists them; a condition with its own page is linked.

refractory diffuse large b-cell lymphoma, relapsed diffuse large b-cell lymphoma